Brief: Precision Biosciences Receives Approval In Hong Kong To Expand Pbgene-Hbv Phase 1 Eliminate-B Trial
18/12/2024 12:41
Dec 18 (Reuters) - Precision BioSciences Inc DTIL.O :
* PRECISION BIOSCIENCES RECEIVES APPROVAL IN HONG KONG TO
EXPAND
PBGENE-HBV PHASE 1 ELIMINATE-B TRIAL FOR THE TREATMENT OF
CHRONIC HEPATITIS B
* PRECISION BIOSCIENCES INC - U.S. IND FOR PBGENE-HBV
ANTICIPATED
IN 2025
Source text: ID:nBwtQ2qna
Further company coverage: DTIL.O
Recent news on Precision Biosciences
See all newsPrecision BioSciences Inc reports results for the quarter ended June 30 - Earnings Summary
Precision BioSciences Q2 net loss widens on warrant liability charge
Precision BioSciences Inc expected to post a loss of 79 cents a share - Earnings Preview
Precision BioSciences Inc expected to post a loss of 79 cents a share - Earnings Preview
Brief: Precision Biosciences - Enters First Amendment To Loan And Security Agreement With Banc Of California - SEC Filing